Primary Immune Thrombocytopenia
Conditions
Interventions
Group 1:Using cyclosporine A for treatment
Group 2:Using azathioprine for treatment
Control group:Treatment with glucocorticoids
Sponsors
the Second Affiliated Hospital of Kunming Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-75, male and female; 2. It meets the following diagnostic criteria for ITP (according to the 2016 version of Chinese expert consensus on diagnosis and treatment of adult primary immune thrombocytopenia): 2 or more laboratory blood routine examinations showed decreased platelet count and no abnormal blood cell morphology; 3. Spleen generally not enlarged; 4. The number of megakaryocytes in bone marrow examination was increased or normal, and there was maturation disorder; 5. Platelet count =30x10^9/L but bleeding; 6. Patients who had been treated with glucocorticoid but had poor efficacy or had contraindications for adrenocorticoid use; 7. Patients with ITP who failed splenectomy; 8. ITP patients who failed to respond to other second-line drugs;Voluntary hospitalization and informed consent.
Exclusion criteria
Exclusion criteria: 1. Received chemotherapy, anticoagulant drugs or other treatments that might affect platelet count in the first 3 weeks of the study; 2. Serious heart, lung, liver, renal insufficiency diseases; 3. Severe immunodeficiency, or systemic autoimmune disease; 4. Patients with severe hypertension; 5. The investigator considers it inappropriate to participate in any other condition of this trial; 6. All kinds of congenital thrombocytopenia, pseudothrombocytopenia and other secondary thrombocytopenia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| platelets counts; | — |
Countries
China
Contacts
Public ContactZeping Zhou
The Second Affiliated Hospital of Kunming Medical University
Outcome results
None listed